Yavuz Gökce, Spicer Jonathan D
Division of Thoracic Surgery, McGill University Health Center, 1650 Cedar Avenue, Montreal, Quebec, H3H 1V6, Canada.
Division of Thoracic Surgery, McGill University Health Center, 1650 Cedar Avenue, Montreal, Quebec, H3H 1V6, Canada.
Thorac Surg Clin. 2026 Feb;36(1):9-23. doi: 10.1016/j.thorsurg.2025.09.008.
Neoadjuvant treatment strategies for early-stage resectable non-small cell lung cancer (NSCLC) are evolving with the introduction of immune checkpoint inhibitors. While traditional neoadjuvant chemotherapy has offered modest survival benefit, recent trials show that combining chemotherapy with immunotherapy significantly increases pathologic complete response rates and event-free survival, without raising perioperative risks. Ongoing research aims to refine biomarker-driven strategies and integrate advanced tools to better personalize treatment. While long-term survival data are still maturing, current evidence suggests that neoadjuvant chemoimmunotherapy is a significant advancement in the multimodal management of resectable NSCLC and a likely cornerstone of future standard care for early-stage disease.
随着免疫检查点抑制剂的引入，早期可切除非小细胞肺癌（NSCLC）的新辅助治疗策略正在不断发展。虽然传统的新辅助化疗带来了一定的生存获益，但最近的试验表明，将化疗与免疫疗法相结合可显著提高病理完全缓解率和无事件生存率，且不会增加围手术期风险。正在进行的研究旨在完善生物标志物驱动的策略，并整合先进工具以更好地实现治疗个体化。虽然长期生存数据仍在完善中，但目前的证据表明，新辅助化疗联合免疫疗法是可切除NSCLC多模式治疗中的一项重大进展，并且可能成为早期疾病未来标准治疗的基石。
